Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its …
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to …
1. Record run Here are the most important news items that investors need to start their trading day: The S&P 500 closed above 5,000 on Friday for the first time …
The Biogen headquarters in Cambridge, Massachusetts, on Tuesday, Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of …
As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason …
2023 wasn’t a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. …
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be …
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The …
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to …
Much of the gains in the S & P 500 this year can be attributed to the “Magnificent Seven” stocks. The group comprises Apple , Amazon , Alphabet , Meta …